Evrópusambandið - íslenska - EMA (European Medicines Agency)

fgk representative service gmbh - sufentaníl - verkir, eftir aðgerð - svæfingarlyf - zalviso er ætlað til meðferðar við bráðum í meðallagi til alvarlega verkja eftir verkun hjá fullorðnum sjúklingum.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 40 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

grünenthal gmbh* - esomeprazolum magnesíum - magasýruþolin tafla - 20 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

grünenthal gmbh* - esomeprazolum magnesíum - magasýruþolin tafla - 40 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

grünenthal gmbh* - esomeprazolum magnesíum - mixtúrukyrni, dreifa - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

grünenthal gmbh* - esomeprazolum natríum - stungulyfs-/innrennslisstofn, lausn - 40 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - krabbamein, lungnakrabbamein - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.